Table 1.

Demographic features and outcome in VKC patients treated with omalizumab in the present case series and in the literature

Authors	n	Patient #	Before omalizumab
			Age	Gender	Atopy	Allergy (prick tests + specific seric IgE)	Blood total IgE (KUI/L)	Ocular history	Previous treatments
Current paper
Doan et al. [1]	4	1	13	Male	Asthma rhinitis	Grass pollens, fagaceae, alternaria, cat dander, cow milk, eggs	146	Palpebral form	Continuous topical steroids and CsA
		2	10	Male	Asthma, rhinitis	Grass pollens, dust mites, alternaria, nuts	1655	Palpebral and limbal form Vernal plaque OS Supratarsal steroid injections	Topical steroids 8 months/year and continuous topical CsA supratarsal steroid injections OS
		3	7	Male	Asthma, eczema, rhinitis	Grass pollens, birch, peanuts, eggs, kiwi	8000	Palpebral and limbal form	Continuous topical steroids and CsA
		4	7	Male	Asthma	None	141	Palpebral form Supratarsal steroid injection OS	Continuous topical steroids and CsA supratarsal steroid injections OS
Literature review
Sanchez et al. [18]	1	5	15	Male	Asthma, eczema, rhinitis	Dust mites	340		Tacrolimus ointment on lids and eyes
de Klerk et al. [15]	1	6	12	Male	Asthma, eczema, rhinitis	?	?	Vernal plaque OR Supratarsal steroid injections	CsA OU supratarsal steroid injection OR
Heffler et al. [19]	2	7	9	Female	None	None	?		Topical steroids, CsA, tacrolimus; oral steroids
		8	21	Male	Eczema	None	?		Topical steroids, CsA, tacrolimus; oral steroids

Authors	n	Patient #	Outcome on omalizumab
			Delay for improvement	Dosing of OMZ	Efficacy on VKC	Ocular symptoms	Ocular signs
Current paper
Doan et al. [1]	4	1	3 months	600 mg every 2 weeks	Partial control	VAS 89 => 31 (16 months). Still some inflammatory flares	Grade 4 => 3
		2	6 weeks	600 mg every 2 weeks	Partial control	VAS 72 => 21 (33 months). Still some inflammatory flares	Grade 4 => 3
		3	2 months	450 mg every 2 weeks	Partial control	VAS 90 => 29 (42 months). Still some inflammatory flares	Grade 4 => 3
		4	NA	600 mg every 2 weeks	Failure	VAS 100 => 100	Grade 4 => 4
Literature review
Sanchez et al. [18]	1	5	6 weeks	300 mg every 2 weeks	Total control	VAS 50 => 20 (18 months)	Disappearance of giant papillae
de Klerk et al. [15]	1	6	8 weeks	300 mg every month	Total control	RQLQ 150 => 3	Disappearance of keratitis and giant papillae
Heffler et al. [19]	2	7	2 months	300 mg every month	Total control	Disappearance of symptoms	Disappearance of redness and giant papillae
		8	5 months	600 mg every month	Partial control	Partial reduction of symptoms	Disappearance of giant papillae, reduction of redness

Authors	n	Patient #	Outcome on omalizumab
			Treatment associated with OMZ	Asthma	Eczema	Rhinitis	Duration of OMZ treatment (months)
Current paper
Doan et al. [1]	4	1	Rescue topical steroids 6 weeks/year continuous topical CsA, MCS and AH1	Total control ACT 24/25 => 24/25 (1 month)	NA	Partial control SFAR 15/16 => 10/16 (16 months)	16 (stopped)
		2	Rescue topical steroids 4 weeks/year continuous topical CsA, MCS and AH1	Total control ACT 20/27 => 24/27 (4 months)	NA	Partial control SFAR 14/16 => 13/16 (33 months)	33 (ongoing)
		3	Rescue topical steroids 8 weeks/year continuous MCS and AH1	Total control ACT 27/27 => 27/27 (1 month)	Total control SCORAD 56 => 5 (9 months)	Partial control SFAR 15/16 => 11/16 (42 months)	42 (ongoing)
		4	Continuous topical steroids, CsA, MCS and AH1 + oral steroid pulses	Failure ACT 3/27 => 5/27 (6 months)	NA	NA	6 (stopped)
Literature review
Sanchez et al. [18]	1	5	Continuous topical tacrolimus	Total control after 2 months	Total control after 6 months	?	18
de Klerk et al. [15]	1	6	None	Marked improvement	Partial control	Total control	18
Heffler et al. [19]	2	7	Rescue topical antihistamines	NA	NA	NA	6 (stopped)
		8	Rescue topical antihistamines	NA		NA	6 (stopped)

NA non-applicable, OMZ omalizumab, MCS mast cell stabilizers, AH1 antihistamines H1, CsA cyclosporine A eye drops, VAS Visual Analog Scale, RQLQ Rhinoconjunctivitis Quality of Life Questionnaire, ACT Asthma Control Score, according to [22]—the higher the better, SFAR Score For Allergic Rhinitis, according to [23], SCORAD Score for Atopic Dermatitis, according to [24]